Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Many people with ongoing medical conditions experience more symptoms during the winter. Here's why, and what you can do.

Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. | Arcutis ...

R Squared Ltd bought a new position in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the fourth quarter, ...

Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical foam for seborrheic dermatitis. Those ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 29.Maximize Your Portfolio ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a ...